Compositions and methods to modulate cell membrane resealing

Patent metadata

Field	Value
Publication number	US-9458465-B2
Application number	US-32864608-A
Country	US
Kind code	B2
Filing date	Dec 4, 2008
Priority date	Dec 4, 2007
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

Disclosed herein are compositions and methods for repairing cell membranes. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the repair of cell membranes. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with cell membrane damage.

First claim

The invention claimed is:

1. A composition comprising an effective amount of a mitsugumin53 (MG53) polypeptide sufficient to treat a tissue damage or injury related disease or disorder, wherein the MG53 polypeptide has at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO. 1, a pharmaceutically acceptable carrier, and an agent capable of modulating, synergistically, the membrane repair activity of MG53 selected from the group consisting of a zinc ionophore, an oxidizing agent, and notoginsing.

2. The composition of claim 1 , wherein the MG53 polyeptide is bound or complexed with at least one member selected from the group consisting of CSN6, kinesin, caveolin-3, periaxin, and myelin-basic-protein, wherein the complex facilitates cell membrane repair.

3. A method of treating a pathological condition related to cell membrane damage comprising administering to an individual an effective amount of the composition of claim 1 wherein the composition is effective in ameliorating the effects of the pathological condition.

4. The composition of claim 1 , wherein the agent capable of modulating, synergistically, the membrane repair activity of MG53 is phosphotidylserine.

5. The composition of claim 1 , wherein the agent capable of modulating, synergistically, the membrane repair activity of MG53 is notoginsing.

6. The composition of claim 1 , wherein the agent capable of modulating, synergistically, the membrane repair activity of MG53 is an oxidizing agent.

7. A method of treating cell membrane damage comprising administering extracellularly the composition of claim 1 , wherein the composition is effective in treating cell membrane damage.

8. The method of claim 7 , wherein the composition comprises notoginsing.

9. The method of claim 7 , wherein the composition comprises an oxidizing agent.

10. The method of claim 7 , wherein the composition is administered to a cell in vitro.

11. The method of claim 7 , wherein the composition is administered to a cell in vitro.

12. The method of claim 7 , wherein the cell is at least one of a fibroblast cell, epithelial cell, ovary cell, kidney cell, neuronal cell, keratinocyte, dental cell, gastric cells, immune cells, skeletal muscle, cardiac muscle cell or combination thereof.

13. The method of claim 3 , wherein the pathological condition is selected from the group consisting of muscle or vascular cell/tissue injury, tissue injury that occurs as a result of cardiovascular disease, myocardial infarction or rigorous physical activity, sports-related injuries, muscular dystrophy, cardiac ischemia, heart failure, aging degeneration, neurodegeneration, sepsis, bacterial infection, gingivitis, gum recession, periodontal disease, wrinkle protection, dermal abrasion, UV damage, nitrogen mustard (chemical blistering agents), ulcers, COPD, wound healing, geriatric medicine, anti-inflammatory, and any combination thereof.

14. The method of claim 13 , wherein the composition comprises notoginsing.

15. The method of claim 13 , wherein the composition comprises an oxidizing agent.

16. The method of claim 13 , wherein the composition is administered in at least one form selected from the group consisting of a lotion, spray, gel, suave, liquid, paste, aerosol, powder, injectable, transdermal application.

17. The method of claim 16 , wherein the form is adapted for topical administration.

Assignees

• Weisleder Noah
• Cai Chuanxi
• Ma Jianjie
• Univ Rutgers

Inventors

• Weisleder Noah
• Cai Chuanxi
• Ma Jianjie

Classifications

• C07K14/4716

  Muscle proteins, e.g. myosin, actin · CPC title

• C12N9/93

  Ligases (6) · CPC title

• A61K38/53

  Ligases (6) · CPC title

• C12N15/62 Primary

  DNA sequences coding for fusion proteins · CPC title

• A61K38/17

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title